With novel payload categories such as degraders, RNA polymerase II inhibitors, immunomodulators, gene silences, and splice modulators entering the clinic, don't miss this opportunity to meet with ...

Antibody drug conjugates (ADCs) mark a new era in targeted cancer therapy, delivering potent cytotoxic chemotherapy via monoclonal antibodies directly into the tumor cells — an era with potentially ...